Loading…
Makes prosthetic limbs, orthotic braces and compression products for mobility and rehabilitation.
Makes prosthetic limbs, orthotic braces and compression products for mobility and rehabilitation.
Sells products to prosthetists and orthotists and increasingly owns clinics that fit and service them, so it earns both the product and the patient-care margin. Insurers and healthcare systems pay for the devices, so reimbursement policy matters. Formerly Össur, it was renamed Embla Medical in 2023.
Moat: narrow (brand, IP / patents, distribution). Long-standing brand and clinical relationships with prosthetists, plus patented bionic/microprocessor technology.
Headquarters: Reykjavik, Iceland · Founded: 1971 · Employees: 4,192
Size Embla Medical hf (EMBLA.CO) is a Denmark Health Care company (Medical Specialties) with a market value of $1.75B, the 36th largest of 59 Denmark companies the cockpit tracks. Shares closed at DKK 27.95 on 6 Nov 2026.
Performance Over six months the shares gained 2.8%, against -4.0% for the median peer and +8.8% for the Denmark market (cap-weighted) — 10th highest of 20 in its peer set.
Growth Revenue grew 6.0% over the last twelve months (peer median +11.6%); the operating margin is 13.6% (peer median 11.3%).
Valuation It trades at 17.9× forward earnings against a peer median of 27.6× (6th cheapest of 18).
Price implies For today's price to make sense, revenue must grow about -2% a year for seven years (Req g). Recent delivered growth is +8%, so the hurdle is -10 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 2.6 points above its cost of capital (5.0% WACC).
Next results Next results expected around 2 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | DKK 6.41B | DKK 6.14B | DKK 5.89B | DKK 5.41B | DKK 5.09B |
| Revenue growth | — | +4% | +9% | +6% | — |
| Gross profit | DKK 3.72B | DKK 3.57B | DKK 3.45B | DKK 3.13B | DKK 2.89B |
| EBITDA | DKK 1.28B | DKK 1.23B | DKK 1.16B | DKK 947M | DKK 952M |
| Net income | DKK 607M | DKK 551M | DKK 471M | DKK 402M | DKK 301M |
| Free cash flow | DKK 764M | DKK 758M | DKK 632M | DKK 449M | DKK 313M |
| Capital expenditure | DKK 165M | DKK 214M | DKK 270M | DKK 291M | DKK 184M |
| Total debt | DKK 3.23B | DKK 3.44B | DKK 3.60B | DKK 3.16B | DKK 3.35B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Embla Medical hf EMBLA.CO | $1.75B | +3% | +6% | 14% | 17.9× | -1.8% |
| Ottobock SE & Co. KGaA OBCK.DE | $3.36B | -25% | +5% | 15% | 15.4× | 3.5% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | EMBLA.CO | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +0.7% | -1.9% | 9th highest of 21 |
| 6-month return | +2.8% | -4.0% | 10th highest of 20 |
| Distance from 52-week high | -26.2% | -22.1% | 8th lowest of 21 |
| Revenue growth (TTM) | +6.0% | +11.6% | 9th lowest of 21 |
| Operating margin | 13.6% | 11.3% | 10th highest of 21 |
| Forward P/E | 17.9× | 27.6× | 6th cheapest of 18 |
| Growth the price implies (Req g, 7 yrs) | -1.8% | 11.4% | 4th least demanding of 15 |
| Growth delivered (Del g) | +8.3% | +13.4% | 6th lowest of 15 |
| Hurdle (Req g minus delivered) | -10.1 pp | -3.8 pp | 5th least demanding of 15 |
| ROIC minus cost of capital | +2.6 pp | +2.5 pp | 11th highest of 21 |
| EV / EBITDA | 11.2× | 20.8× | 4th cheapest of 13 |
| Net debt / EBITDA | 2.1× | -0.1× | 3rd most indebted of 14 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Embla Medical hf EMBLA.CO | Denmark | $1.75B | +3% | +6% | 14% | 17.9× | -1.8% | +8.3% |
| Fukuda Denshi 6960.T | Japan | $1.75B | -5% | 0% | 19% | 14.6× | -3.2% | -1.0% |
| Angelalign Technology 6699.HK | Hong Kong | $1.74B | -7% | +84% | 9% | 52.1× | 18.1% | +25.8% |
| Poly Medicure POLYMED.NS | India | $1.73B | -4% | +18% | 17% | 40.6× | n/a | n/a |
| Kestra Medical Technologies KMTS | United States | $1.72B | +37% | +61% | -134% | n/a | n/a | n/a |
| Cofoe Medical Technology 301087.SZ | China | $1.71B | -5% | +33% | 10% | 26.9× | 12.5% | +7.4% |
| Butterfly Network BFLY | United States | $1.70B | +53% | +39% | -36% | n/a | n/a | n/a |
| Wuxi Unicomp Technology 688531.SS | China | $1.80B | -36% | +53% | 12% | 40.7× | n/a | n/a |
| ChemoMetec A/S CHEMM.CO | Denmark | $1.69B | +124% | +3% | 49% | 52.0× | 17.9% | +12.7% |
| Medartis MED.SW | Switzerland | $1.83B | +47% | +30% | 2% | 74.2× | n/a | n/a |
| Rigaku 268A.T | Japan | $1.66B | -57% | +5% | 15% | 20.4× | 18.8% | +14.5% |
| Inner Mongolia Furui Medical Science 300049.SZ | China | $1.85B | -5% | +11% | 25% | 53.2× | 6.6% | +14.6% |
| LeMaitre Vascular LMAT | United States | $1.85B | -25% | +12% | 29% | 26.2× | 2.9% | +14.0% |
| Inspire Medical Systems INSP | United States | $1.85B | +45% | 0% | 2% | 45.4× | 30.9% | +51.2% |
| Molbio Diagnostics MOLBIO.NS | India | $1.63B | n/a | +35% | 17% | n/a | n/a | n/a |
| Vitrolife VITR.ST | Sweden | $1.63B | +14% | -2% | 19% | 27.6× | 22.0% | +22.5% |
| Nihon Kohden 6849.T | Japan | $1.63B | +8% | +1% | 7% | 17.6× | -2.1% | +3.3% |
| DENTSPLY SIRONA XRAY | United States | $1.89B | -14% | -1% | 5% | 7.3× | 10.2% | +1.9% |
| Draegerwerk AG & Co. KGaA DRW8.DE | Germany | $1.89B | +17% | +5% | 7% | 9.4× | -12.6% | +0.4% |
| Shanghai MicroPort Endovascular MedTech 688016.SS | China | $1.59B | -14% | +16% | 44% | 17.2× | 3.1% | +23.4% |
| SKAN SKAN.SW | Switzerland | $1.92B | +49% | +9% | 11% | 49.8× | 13.8% | +11.7% |